ArticleBritish journal of cancer1998
Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 81 citations in OpenAlex.
- Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.International journal of molecular sciences · 2019Trial
- The Investigation of the Association Between theClinical Medicine Insights. Oncology · 2023Article
- Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.BMC cancer · 2014Article
- Lessons learned from gene expression profiling of cutaneous T-cell lymphoma.The British journal of dermatology · 2013Review
- Apoptotic activity in Libyan breast cancer.World journal of surgical oncology · 2012Article
- Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer.Journal of cancer research and clinical oncology · 2012Article
- CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours.Cancer immunity · 2009Article
- P53 and BCL-2 as prognostic markers in endometrial carcinoma.Pathology oncology research : POR · 2008Article
- Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.Oncogene · 2006Review
- A prognostic index for operable, node-negative breast cancer.British journal of cancer · 2004Article
- BRCA1 functions as a breast stem cell regulator.Journal of medical genetics · 2004Review
- Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.British journal of cancer · 2003Article
- Plasma bcl-2 and nitric oxide: possible prognostic role in patients with metastatic breast cancer.Medical oncology (Northwood, London, England) · 2001Article
- Low expression of bcl-2 in Brca1-associated breast cancers.British journal of cancer · 2000Article
- Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors.British journal of cancer · 2000Article
- Number of apoptotic cells as a prognostic marker in invasive breast cancer.British journal of cancer · 2000Article
- Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy.Breast cancer research : BCR · 2000Review
- Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.Journal of neuro-oncology · 1999Article
- bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.Clinical & experimental metastasis · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bcl-2 has been demonstrated to inhibit apoptosis in breast cancer cells in vitro, and the ratio between Bcl-2 and its proapoptotic homologue Bax seems to be an important determinant of cellular sensitivity to induction of apoptosis. However, little information is available on the relationship between Bcl-2 and the rate of apoptotic and necrotic cell death in breast tumours. From a series of 441 premenopausal, lymphnode-negative breast cancer patients, a subset of 49 tumours was selected in which immunostaining for the 26-kDa isoform of Bcl-2 was either absent (n = 23) or very high (n = 26). High expression of Bcl-2 was found to be strongly associated with low rates of apoptotic (P < 0.001) and necrotic cell death (P < 0.001). The mean value of the apoptotic index was 2.69%+/-1.40% in Bcl-2-negative tumours and 0.68%+/-1.00% in Bcl-2-positive tumours. Expression of the proapoptotic protein Bax correlated neither with Bcl-2 nor with the frequency of apoptotic cells. Immunostaining for the antiapoptotic Bcl-2 homologue BcI-X(L) correlated with Bcl-2 expression (P < 0.001) but not with apoptosis. High proliferation rate and high tumour grade (Bloom-Richardson) were strongly associated with absence of Bcl-2 expression (P< 0.001). p53 accumulation was associated with absence of Bcl-2 expression and increased apoptotic activity. Loss of Bcl-2 expression was strongly correlated with increased apoptotic and necrotic cell death, high proliferation rate and high tumour grade, supporting a model in which Bcl-2 not only mediates cell death, but also cell division in breast cancer tissue, and in which regulation of cell division and cell death are tightly linked.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.